Use of a Novel, Self-Expanding Coronary Sinus Reducer to Treat Symptomatic Epicardial and Microvascular Ischemic Heart Disease: Preclinical and First-in-Human Experience
The A-FLUX CSR demonstrates preclinical and clinical procedural safety coupled with promising short-term clinical efficacy in persistently symptomatic patients with both CMD and obstructive CAD.
Institutions
- Cedars-Sinai Medical Center (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- Utrecht University (NL)
- Medical University of Warsaw (PL)
- University Hospital Complex Of Vigo (ES)
- University Medical Center Utrecht (NL)
- Yale University (US)
- Lung Institute (US)
- Hospital Clínic de Barcelona (ES)
- Cedars-Sinai Smidt Heart Institute (US)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Journal of the Society for Cardiovascular Angiography & Interventions
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1016/j.jscai.2025.104070
- Primary Topic
- Pain Management and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00